Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab.

× No keyword cloud information.

4 in total

1. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Authors: Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo
Journal: JAMA Date: 2016-08-16 Impact factor: 56.272

2. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors: Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245

3. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245

4. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.

Authors: Alejandro Arrieta; Timothy F Page; Emir Veledar; Khurram Nasir
Journal: PLoS One Date: 2017-01-12 Impact factor: 3.240

4 in total

1 in total

1. 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.

Authors: Lieven Annemans; Chris J Packard; Andrew Briggs; Kausik K Ray
Journal: Eur Heart J Date: 2018-07-14 Impact factor: 29.983

1 in total